POLYCYTHEMIA VERA THERAPEUTICS MARKET ANALYSIS

Polycythemia Vera Therapeutics Market, by Disease Type (Primary Polycythemia Vera and Secondary Polycythemia Vera), by Drug Class (Antimetabolite, Kinase Inhibitors, Alpha Interferon, Selective Serotonin Reuptake Inhibitors, and Others), by Route of Administration (Oral, Intravenous, Intramuscular, and Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Jul 2021
Code : CMI4540
Pages :218
Formats :
Excel and PDF
Industry : Pharmaceutical

Polycythemia Vera Therapeutics MarketSize and Trends

The global polycythemia vera therapeutics market is estimated to be valued at US$ 1,115.9 million in 2021 and is expected to exhibit a CAGR of 4.5% over the forecast period (2021-2028).

The increasing incidence of polycythemia vera is expected to drive the growth of the global polycythemia vera therapeutics market over the forecast period.

Figure 1. Global Polycythemia Vera Therapeutics Market Share (%), By Region, 2021

The increasing research and development activities for the development of novel therapeutics for the treatment of polycythemia vera is expected to drive the market growth over the forecast period.

Figure 2. Global Polycythemia Vera Therapeutics Market Value (US$ Mn), By Drug Class, 2021

Polycythemia Vera Therapeutics Market Report Coverage

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa